SAVA - Cassava Sciences: New Year Same Game Of Smoke And Mirrors

2024-03-25 13:50:25 ET

Summary

• Cassava Sciences, Inc. reported $121.1m of cash and a net loss of $(97.2m) for the year 2023.
• The company's research and development expenses increased to $89.4m in 2023.
• Cassava's CEO remains optimistic about the Phase 3 program of its drug candidate, simufilam, for Alzheimer's disease.
• Investors will doubtless be familiar with the massive share price swings and battles between shorts and longs that dictate their direction.
• In this post I recap the history, update on latest developments, and offer some thoughts as to whether simufilam has any chance of meeting endpoints in its >1,000 patient rethink-alz and refocus-alz studies. Rethink data may become available this year.

Investment Overview

Cassava Sciences, Inc. ( SAVA ) released its full year 2023 earnings and corporate updates on February 28th this year.

The company reported $121.1m of cash, and a net loss for the year of $(97.2m), or $(2.32) per share, up from $(76.2m), or $(1.9) per share in the prior year....

For further details see: